# Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil

> **NCT04948411** · — · COMPLETED · sponsor: **Latin American Cooperative Oncology Group** · enrollment: 33 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04948411
- **Lead sponsor:** Latin American Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-30
- **Primary completion:** 2023-02-01
- **Final completion:** 2023-02-01
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2024-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04948411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04948411, "Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04948411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*